Moderna’s Covid Vaccine Receives Full Authorization for Use by the FDA

La vacuna de Moderna se comercializará bajo el nombre de Spikevax.

Moderna’s vaccine will be marketed under the name Spikevax.

Photo: FREDERIC J. BROWN/AFP/Getty Images

This Monday the United States Food and Drug Administration (FDA) issued a statement in which it reported its decision to grant its full authorization for the application of the Covid vaccine created by Modernawhich only had the approval of this authority for emergency use.

In the text, the FDA indicated that after its decision this will allow Moderna’s vaccine can be marketed under the name Spikevax, which can only be applied to people over 18 years of age.

Moderna’s vaccine has thus become the second vaccine against Covid to receive full approval by the FDA; the first to obtain it was from Pfizer.

The outgoing FDA commissioner, Janet Woodcock, noted that full approval “may instill greater confidence in making the decision to get vaccinated” among the population, since it lasts indefinitely as long as it is not presented or know of any side effect that you were not aware of.

For Moderna’s vaccine to obtain this type of authorization, it had to provide extensive data on the manufacturing process, in addition to being subject to constant meticulous inspections by the FDA.

Stéphane Bancel, CEO of Moderna, said in a statement that “All of the actual data and full (approval) of Spikevax in the US reaffirms the importance of vaccination against this virus“.

“This is a momentous milestone in Moderna’s history as it is our first product to be licensed in the US,” he added.

It may interest you:

* Moderna will work from January on an adaptation of its vaccine for the Omicron variant
* Covid: two decisive advances in the next vaccines to try to end the pandemic
* COVID: Down, numbers of daily infections and hospitalized patients in Los Angeles County


See also  Pre-existing immunity: the reason some have never had COVID

Leave a Comment

Your email address will not be published.